A Phase I Study of LY2940680 in Patients with Advanced Basal Cell Skin Cancer

Protocol
13-005
Full Title
A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer
Phase
I
Purpose

The purpose of this study is to assess the safety and effectiveness of an investigational drug called LY2940680 in patients with advanced basal cell carcinoma, a type of skin cancer. LY2940680 works by blocking the action of a protein called Smoothened, which is important for the growth of many basal cell cancers. It is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced or metastatic basal cell carcinoma.
  • At least 4 weeks must have passed since the completion of prior therapies (3 weeks for other investigational drugs) and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.

Disease(s)
Basal Cell Carcinoma
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »